Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Unlock Full TWST Analysis
UpgradeKey Numbers
Market Cap
$4B
P/E
N/A
Revenue Growth
+28.0%
Gross Margin
N/A
ROE
N/A
About Twist Bioscience
As a small-cap biotech company trading on the NASDAQ, Twist Bioscience has established itself, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Synthetic biology company manufacturing synthetic DNA for research and therapeutics. With a $4B market capitalization and no current profitability, Twist Bioscience has delivered healthy growth momentum with revenue moving +28% over the past year.
Expert Coverage
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.